7 Results for "

AAV-HBV

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "AAV-HBV" in MCE Product Catalog:

Cat. No.: HY-177022
CAS No.: 2495324-66-6
Target:  

HBV

Research Areas:  

Infection

ALG-001075, a capsid assembly modulator (CAM), is an orally active HBV inhibitor. ALG-001075 effectively blocks not only HBV DNA production but also extracellular HBsAg/HBeAg and intracellular HBV RNA in primary human hepatocytes. ALG-001075 shows pronounced reductions of circulating HBV DNA in the AAV-HBV mouse model. ALG-001075 can be used for the study of Chronic hepatitis B (CHB) .
loading...
    loading...
Cat. No.: HY-145579
CAS No.: 1808248-05-6
Purity:  98.14%
Synonyms: RG7907; RO7049389
Target:  

HBV Apoptosis

Research Areas:  

Infection Inflammation/Immunology

Linvencorvir (RG7907) is an orally active Hepatitis B virus core protein allosteric modulator. Linvencorvir induces Apoptosis. Linvencorvir has antiviral activity against HBV .
loading...
    loading...
Cat. No.: HY-145592
CAS No.: 1948241-60-8
Purity:  99.92%
Synonyms: RO7020531; RG7854
Research Areas:  

Infection

Ruzotolimod (RO7020531) is an orally active TLR7 agonist. Ruzotolimod inhibits WHV viral replication and, in combination with RO-7049389 (HY-145579), inhibits AAV-HBV viral load. Ruzotolimod can be used to study infection with COVID-19 or SARS-CoV-2 .
loading...
    loading...
Cat. No.: HY-174819
CAS No.: 2396680-45-6
Target:  

HBV

Research Areas:  

Infection

VNRX-9945 is a potent, broadly and orally active HBV CAM (capsid assembly modulator) with an EC50 of 2.6 nM. VNRX-9945 exhibits excellent and broad antiviral activity against multiple HBV genotypes in vitro, along with favorable pharmacokinetic profiles across multiple species. VNRX-9945 demonstrates robust antiviral efficacy in the adeno-associated virus mice models of HBV (AAV-HBV) infection .
loading...
    loading...
Cat. No.: HY-177300
CAS No.: 1402802-45-2
TLR7/8 agonist 13 is an orally active dual agonist of TLR7 (lowest effective concentrations (LEC) [hTLR7] = 1.6 μM) and TLR8 (LEC [hTLR8] = 1.6 μM). TLR7/8 agonist 13 exhibits agonistic activity against human peripheral blood mononuclear cells (hPBMCs) (LEC [hPBMC] = 0.5 μM). TLR7/8 agonist 13 induces endogenous IFNα, activating myeloid dendritic cells and monocytes toward a TH1 phenotype in mice and cynomolgus monkeys. TLR7/8 agonist 13 reduces viral load and HBV surface antigen expression in a mouse model of chronic AAV-HBV infection. TLR7/8 agonist 13 has the potential to indirectly induce IFNγ, which may promote HBV antigen-specific CD8 T cell-mediated responses. TLR7/8 agonist 13 can be used to study hepatitis B virus .
loading...
    loading...
Cat. No.: HY-149357
CAS No.: 2569526-80-1
Target:  

HBV

Research Areas:  

Infection

Yhhu6669 is an anti-HBV agent. Yhhu6669 inhibits HBV DNA. Yhhu6669 inhibits HBV replication by inducing the formation of DNA-free capsids. Yhhu6669 decreases HBV DNA and HBcAg in AAV/HBV-infected mice. Yhhu6669 has favorable PK properties .
loading...
    loading...
Cat. No.: HY-183576
Target:  

HBV

Research Areas:  

Infection Neurological Disease

HBsAg-IN-1 is an orally active, highly liver-selective inhibitor of HBsAg production, with an EC50 of 0.63 nM. HBsAg-IN-1 shows no neurite growth inhibitory activity. HBsAg-IN-1 can be used in studies related to hepatitis B virus (HBV) infection .
loading...
    loading...